Collaboration with Sanofi on cryo-EM based structure research

Waltham, USA, & Villigen, Switzerland, 13rd of December 2018–leadXpro AG announced today that it has entered into an agreement  with Sanofi to enable their structure based drug discovery efforts using leadXpro’s single particle cryo-Electron Microscopy (cryo-EM) capabilities.

In the research project, Sanofi and leadXpro will combine their expertise in structure based drug discovery for a challenging drug target. In particular, leadXpro will contribute protein sample generation and enable structure determination by high resolution cryo-electron microscopy to inform about the interaction with small molecule ligands aiming to facilitate the discovery and optimization of novel lead molecules.

Wassim Abdul Rahman, project leader at leadXpro said: “We’re excited applying cutting edge methods and in house developed unique expertise for expression, solubilization and purification to generate high quality protein samples and structures suitable to visualize the ligand interaction by cryo-EM experiments. This effort redefines discovery of new lead molecules for this challenging protein target”.

Financial terms of the partnership were not disclosed.

About leadXpro AG

leadXpro is a drug discovery company focusing on membrane protein targets such as GPCR’s, ion-channels and transporters. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds with unmet efficacy and specificity. leadXpro’s technology platform capitalizes on the expert knowledge regarding membrane protein biochemistry and close collaboration with academic facilities of the Paul Scherrer Institute (PSI) for synchrotron (SLS), X-ray Free Electron Laser (SwissFEL) and the University of Basel (C-CINA) for single particle cryo-electron microscopy (cryo-EM). For more information, please visit

leadXpro is a registered trademark in the EU, Switzerland, US and Canada.